Promoter and Institution shareholding in Lincoln Pharma increased slightly over the past year, diverging from the sector average which saw no change, indicating potential insider confidence amidst broader sector selling.

Public shareholding has decreased significantly, reflecting a lack of retail interest and possible concerns about market conditions, which aligns with the overall trend in the sector.

Comparatively, Lincoln Pharma's stability in smart money (Promoters and Institutions) is overshadowed by the negative public sentiment, indicating a cautious outlook for the stock.